Stuttgart
18.09.26 | 21:46
0,177 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,153 | 0,229 | 19.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Oncopeptides AB: CHMP issues positive opinion of label expansion of Pepaxti to third-line treatment | 335 | GlobeNewswire (Europe) | STOCKHOLM - September 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for... ► Artikel lesen | |
| 27.08. | Oncopeptides Q2 2026 slides: 62% sales growth, 3rd-line expansion | 6 | Investing.com | ||
| 27.08. | Oncopeptides: Umsatz steigt im zweiten Quartal um 62 %, Aktie legt zu | 2 | Investing.com Deutsch | ||
| 27.08. | Oncopeptides AB Q2 Loss Narrows | 3 | RTTNews | ||
| ONCOPEPTIDES Aktie jetzt für 0€ handeln | |||||
| 27.08. | Oncopeptides AB: Oncopeptides publishes Q2 report 2026 | 343 | GlobeNewswire (Europe) | Stockholm - August 27, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 17.08. | Oncopeptides AB: Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe | 569 | GlobeNewswire (Europe) | STOCKHOLM - August 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Public Agency of the Republic of Slovenia... ► Artikel lesen | |
| 08.06. | Oncopeptides AB: First patient enrolled in Oncopeptides' real-world evidence study MARINA in Germany | 565 | GlobeNewswire (Europe) | STOCKHOLM - June 8, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in... ► Artikel lesen | |
| 26.05. | Oncopeptides AB: Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | 405 | GlobeNewswire (Europe) | STOCKHOLM, May 26, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has entered into an agreement with SALUS,... ► Artikel lesen | |
| 21.05. | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides | 287 | GlobeNewswire (Europe) | STOCKHOLM - May 21, 2026 - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 21 May 2026. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
| 13.05. | Oncopeptides AB Q1 Loss Drops | 6 | RTTNews | ||
| 13.05. | Oncopeptides AB: Oncopeptides publishes Q1 report 2026 | 657 | GlobeNewswire (Europe) | Stockholm - May 13, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2026.
"Oncopeptides... ► Artikel lesen | |
| 11.05. | Oncopeptides AB: Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment | 311 | GlobeNewswire (Europe) | STOCKHOLM - May 11, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its intention to submit a Type II variation application... ► Artikel lesen | |
| 17.03. | Oncopeptides AB: Outcome in Oncopeptides' rights issue | 405 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| 16.03. | Oncopeptides AB: Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany | 1.139 | GlobeNewswire (Europe) | STOCKHOLM - March 16, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces the initiation of the MARINA study in close... ► Artikel lesen | |
| 09.03. | Oncopeptides AB: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma | 519 | GlobeNewswire (Europe) | Stockholm, March 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that it has achieved key regulatory agreement... ► Artikel lesen | |
| 24.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.02.2026 | 401 | Xetra Newsboard | Das Instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.02.2026 und ex Kapitalmassnahme am 25.02.2026 The instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY... ► Artikel lesen | |
| 19.02. | Oncopeptides AB: Oncopeptides publishes year-end report 2025 | 396 | GlobeNewswire (Europe) | Stockholm - February 19, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2025.
"Oncopeptides... ► Artikel lesen | |
| 19.02. | Oncopeptides AB: Oncopeptides carries out a rights issue of approximately SEK 200 million | 520 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND... ► Artikel lesen | |
| 15.01. | Oncopeptides AB: Oncopeptides announces Q4 2025 sales and updates cash-flow expectations | 446 | GlobeNewswire (Europe) | Stockholm, January 15, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the fourth quarter of 2025 and... ► Artikel lesen | |
| 05.11.25 | Oncopeptides AB: Oncopeptides publishes Q3 report 2025 | 421 | GlobeNewswire (Europe) | Stockholm - November 5, 2025 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2025.
"The third... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | Biontech-Großaktionär rechnet mit baldiger Vorstands-Neubesetzung | Mainz - Einer der Großaktionäre und Mitgründer von Biontech, Thomas Strüngmann, rechnet mit einer baldigen Neubesetzung im Vorstand des Mainzer Biotechunternehmens."Die Berufung eines neuen Medizinvorstands... ► Artikel lesen | |
| EVOTEC | 2,914 | +1,11 % | Neue Angriffspunkte gegen Krebs! Warum Vidac Pharma, BioNTech und Evotec Aufmerksamkeit verdienen! | Krebszellen nutzen ausgeklügelte Schutzmechanismen, entziehen sich dem Immunsystem und programmieren ihren eigenen Stoffwechsel um. Diese Mechanismen werden nun verstärkt zur Zielscheibe von Biotechgesellschaften.... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| MODERNA | 134,16 | +0,12 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen | |
| VALNEVA | 2,863 | +1,02 % | Valneva-Aktie im Check am 19.09. (10:35 Uhr): Meine aktuelle Lageeinschätzung | ||
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| STRYKER | 238,70 | -0,29 % | Stryker nach Cyberattacke: Was Anleger jetzt wissen müssen | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | -3,28 % | Biofrontera erhält FDA-Zulassung für Hautkrebsbehandlung | ||
| HEIDELBERG PHARMA | 2,470 | -0,40 % | Heidelberg Pharma AG-Aktie im Check am 18.09. (08:39 Uhr): Meine aktuelle Lageeinschätzung | ||
| ILLUMINA | 210,00 | +0,70 % | Biotech Stocks At 52-Week Highs - BlossomHill Therapeutics +18% On Positive Trial Data, Adaptive Biotechnologies, Illumina, CeriBell, Neogen | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.BlossomHill... ► Artikel lesen | |
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen |
ONCOPEPTIDES AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,177 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOPEPTIDES AB finden Sie auf Wallstreet Online.